

Appendix – Clinical Trial Experience in Norway

Phase I

NCT00459550	A Randomised Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients With Alzheimer's Disease	GlaxoSmithKline
(NCT02061722)	Imaging of Phosphodiesterase 10 A (PDE10A) Enzyme Levels in the Living Human Brain of Huntington's Disease Gene Expansion Carriers and Healthy Controls With Positron Emission Tomography	CHDI Foundation, Inc.
NCT02956148)	Follow-up Measurement of Brain Phosphodiesterase 10 A (PDE10A) Enzyme Levels in Huntington's Disease Gene Expansion Carriers, 18 to 28 Months After Initial Positron Emission Tomography (PET) Measurement in CHDIKI1201/PET-HD-PDE10A,	CHDI Foundation, Inc
NCT06234436	Plasma Dilution and Infusion to Improve Cognition in Mild Cognitive Impairment	Oslo University Hospital HF
NCT06774261	A phase 1B dose range finding study of phenserine compared to donepezil in participants with early or mild AD	Helse Stavanger HF

Phase II

NCT00630500	A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies	Helse Stavanger HF
NCT00785759	An Open-label Study to Assess Brain Uptake and Safety of AH110690 (18F) Injection in Subjects With Probable Alzheimer's Disease, Amnesic Mild Cognitive Impairment and Healthy Volunteers, 2008	GE Healthcare
NCT01021696	The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial, 2009	University of Bergen

NCT01097096	A 90-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study in Patients With Mild Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and Abeta-specific Antibody Response Following Repeated i.m. Injections of Adjuvanted CAD106	Novartis Pharmaceuticals
NCT01428453	A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease	GlaxoSmithKline
NCT02788513	A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease	Boehringer Ingelheim
NCT04588285	A Clinical Trial to Demonstrate Clinical Efficacy on Cognitive, Neuropsychiatric and Functional Outcomes of Ambroxol in New and Early Patients With Prodromal and Mild Dementia With Lewy bodies,	Helse Fonna HF
NCT05068830	Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease: The ExPlas Study,	Norwegian University of Science and Technology
NCT05617508	N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease	Haukeland University Hospital
NCT06079190	A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease	GlaxoSmithKline
(NCT06362707)	A Placebo Controlled Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Early Alzheimer's Disease (FEAD)	Helse Stavanger HF
NCT06853743	The NAD-HD Study: A Parallel-group, Phase 2, Double-blind Study to Investigate the Efficacy and Safety of Oral Nicotinamide Riboside Compared With Placebo in	Oslo University Hospital HF

	Participants Aged 18 to 80 Years With Huntington's Disease	
--	--	--

Phase III

NCT00099242	Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease	Novartis Pharmaceuticals
NCT00145691	The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) - An Eight Week Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi Center Trial. A Phase III Study	Sykehuset Innlandet HF
NCT03114657	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease	Hoffmann-La Roche
NCT04777396	A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer's Disease (EVOKE)	Novo Nordisk A/S

Phase IV

NCT00443014	Phase 4 Study of Cognitive Therapy and Donepezil in Alzheimers Disease	University Hospital of North Norway
NCT00433121	Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - an Open Study	Sykehuset Innlandet HF
NCT00594269	Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - a 24 Weeks Double Blind RCT	Sykehuset Innlandet HF
NCT02267057	Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial	University of Bergen)